Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

AbbVie will pay $200 million to acquire privately held Nimble Therapeutics and its pipeline of oral peptide drugs for immune diseases like psoriasis and inflammatory bowel disease, the pharmaceutical ...

Regeneron Pharmaceuticals intends to advance two blood-thinning drugs into Phase 3 testing next year after mid-stage study results showed they matched or surpassed marketed medicines at preventing ...

Dec. 31, 2024 – Jan. 22, 2025 • New York, New York ...

Dec. 24, 2024 – Dec. 31, 2024 • New York, New York ...

Dec. 21, 2024 – Dec. 31, 2024 • New York, NY, USA, New York ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...

Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and ...

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...